FDA OKs Medtronic's Intrinsic ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
Executive Summary
Medtronic has gained US approval to sell its new implantable cardioverter-defibrillator (ICD), which is designed to promote natural heart activity and reduce unnecessary pacing in the right ventricle of the heart. The dual-chamber Intrinsic ICD uses a proprietary feature called Managed Ventricular Pacing (MVP), which enables the defibrillator to automatically adapt the way it paces. Unnecessary pacing has been shown to be harmful in some patients. The company plans to use the MVP feature in its future pacing and defibrillation products.